Nature Communications (Jan 2019)
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling
- Sebastian Scheer,
- Suzanne Ackloo,
- Tiago S. Medina,
- Matthieu Schapira,
- Fengling Li,
- Jennifer A. Ward,
- Andrew M. Lewis,
- Jeffrey P. Northrop,
- Paul L. Richardson,
- H. Ümit Kaniskan,
- Yudao Shen,
- Jing Liu,
- David Smil,
- David McLeod,
- Carlos A. Zepeda-Velazquez,
- Minkui Luo,
- Jian Jin,
- Dalia Barsyte-Lovejoy,
- Kilian V. M. Huber,
- Daniel D. De Carvalho,
- Masoud Vedadi,
- Colby Zaph,
- Peter J. Brown,
- Cheryl H. Arrowsmith
Affiliations
- Sebastian Scheer
- Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University
- Suzanne Ackloo
- Structural Genomics Consortium, University of Toronto
- Tiago S. Medina
- Princess Margaret Cancer Centre, University Health Network
- Matthieu Schapira
- Structural Genomics Consortium, University of Toronto
- Fengling Li
- Structural Genomics Consortium, University of Toronto
- Jennifer A. Ward
- Structural Genomics Consortium, University of Oxford
- Andrew M. Lewis
- Structural Genomics Consortium, University of Oxford
- Jeffrey P. Northrop
- Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University
- Paul L. Richardson
- AbbVie Inc., 1 North Waukegan Rd
- H. Ümit Kaniskan
- Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- Yudao Shen
- Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- Jing Liu
- Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- David Smil
- Structural Genomics Consortium, University of Toronto
- David McLeod
- Ontario Institute for Cancer Research
- Carlos A. Zepeda-Velazquez
- Ontario Institute for Cancer Research
- Minkui Luo
- Chemical Biology Program, Memorial Sloan Kettering Cancer Center
- Jian Jin
- Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- Dalia Barsyte-Lovejoy
- Structural Genomics Consortium, University of Toronto
- Kilian V. M. Huber
- Structural Genomics Consortium, University of Oxford
- Daniel D. De Carvalho
- Princess Margaret Cancer Centre, University Health Network
- Masoud Vedadi
- Structural Genomics Consortium, University of Toronto
- Colby Zaph
- Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University
- Peter J. Brown
- Structural Genomics Consortium, University of Toronto
- Cheryl H. Arrowsmith
- Structural Genomics Consortium, University of Toronto
- DOI
- https://doi.org/10.1038/s41467-018-07905-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Protein methyltransferases (PMTs) are epigenetic regulatory enzymes with significant therapeutic relevance. Here the authors describe a collection of chemical inhibitors and antagonists to modulate most of the key methylation marks on histones H3 and H4, and use the collection to study of the role of PMTs in mouse and human T cell differentiation.
